Skip to main content

Dr. Zhuang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Zhuang's full profile

Already have an account?

  • Office

    1400 Quail St
    Ste 220
    Newport Beach, CA 92660
    Phone+1 949-357-0753

Education & Training

  • Allegheny Health Network Medical Education Consortium (WPH/AGH)
    Allegheny Health Network Medical Education Consortium (WPH/AGH)Fellowship, Hematology and Medical Oncology, 2021 - 2024
  • University of California (Irvine)
    University of California (Irvine)Residency, Internal Medicine, 2018 - 2021
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 2018
  • University of Illinois at Chicago
    University of Illinois at ChicagoBS, Biological Sciences/Chemistry , 2011 - 2014

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2019 - 2025
  • PA State Medical License
    PA State Medical License 2021 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Journal Articles

  • Rapidly growing cutaneous ulcers in the setting of calciphylaxis: a case report  
    Eric Zhuang; Jacob Kibrit; David Arps; Radhika Sreedhar, Open Journal of Clinical and Medical Case Reports, 2018

Abstracts/Posters

  • Efficacy of Sars-Cov-2 Vaccine in Hematopoietic Stem Cell Transplantation and CAR-T Cell Therapy Patients; A Single Study Experience
    Eric Zhuang, M.D., Pragnan Kancharla, M.D., Abraham Attah, M.D., Gina Patrus, B.S., Yazan Samhouri, M.D., Anna Koget, D.O., Prerna Mewawalla, M.D., Santhosh Sadashiv, ..., Transplantation & Cellular Therapy, Salt Lake City, UT, 4/2022
  • A phase II study to evaluate the effects of docetaxel plus lycopene in advanced castrate-resistant prostate cancer
    Eric Zhuang, Edward M. Uchio, Michael B. Lilly, John P. Fruehauf, ASCO Genitourinary Cancers Symposium, San Francisco, CA, 2/2021
  • Open label, phase II study of axitinib, a selective inhibitor of vascular endothelial growth factor receptors, in patients with stage III malignant melanoma
    Eric Zhuang, James G. Jakowatz, Maki Yamamoto, John P. Fruehauf, ASCO Annual Meeting, Chicago, IL, 3/2020

Professional Memberships

Other Languages

  • Chinese (Mandarin)